Sabra Health Care REIT Inc (SBRA) Expected to Announce Quarterly Sales of $161.90 Million

Wall Street brokerages expect that Sabra Health Care REIT Inc (NASDAQ:SBRA) will report $161.90 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Sabra Health Care REIT’s earnings, with the highest sales estimate coming in at $164.40 million and the lowest estimate coming in at $159.26 million. Sabra Health Care REIT reported sales of $62.65 million in the same quarter last year, which indicates a positive year-over-year growth rate of 158.4%. The firm is expected to announce its next quarterly earnings report on Monday, May 14th.

On average, analysts expect that Sabra Health Care REIT will report full-year sales of $161.90 million for the current year, with estimates ranging from $633.73 million to $655.80 million. For the next fiscal year, analysts anticipate that the company will post sales of $667.66 million per share, with estimates ranging from $643.86 million to $687.10 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Sabra Health Care REIT.

How to Become a New Pot Stock Millionaire

Sabra Health Care REIT (NASDAQ:SBRA) last released its earnings results on Wednesday, February 21st. The real estate investment trust reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.30 by $0.27. Sabra Health Care REIT had a net margin of 39.04% and a return on equity of 7.19%. The company had revenue of $166.47 million for the quarter, compared to the consensus estimate of $158.82 million.

A number of research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Sabra Health Care REIT from a “sell” rating to a “hold” rating in a research report on Wednesday, March 28th. Bank of America upgraded shares of Sabra Health Care REIT from an “underperform” rating to a “neutral” rating and set a $20.00 target price on the stock in a research report on Monday, March 26th. Wells Fargo cut their target price on shares of Sabra Health Care REIT from $24.00 to $19.00 and set a “market perform” rating on the stock in a research report on Tuesday, March 20th. They noted that the move was a valuation call. Mizuho upgraded shares of Sabra Health Care REIT from a “neutral” rating to a “buy” rating and set a $24.00 target price on the stock in a research report on Wednesday, March 14th. Finally, BidaskClub upgraded shares of Sabra Health Care REIT from a “strong sell” rating to a “sell” rating in a research report on Thursday, March 8th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $23.45.

Sabra Health Care REIT stock traded down $0.07 during trading hours on Thursday, reaching $17.70. 1,326,293 shares of the company’s stock traded hands, compared to its average volume of 1,744,347. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.99. Sabra Health Care REIT has a fifty-two week low of $15.77 and a fifty-two week high of $29.10. The company has a market cap of $3,155.13, a PE ratio of 7.28, a PEG ratio of 2.32 and a beta of 0.65.

Large investors have recently made changes to their positions in the stock. Ffcm LLC raised its position in shares of Sabra Health Care REIT by 1,297.4% in the 4th quarter. Ffcm LLC now owns 5,897 shares of the real estate investment trust’s stock valued at $112,000 after acquiring an additional 5,475 shares during the period. MANA Advisors LLC acquired a new stake in Sabra Health Care REIT during the 4th quarter worth approximately $193,000. BB&T Securities LLC acquired a new stake in Sabra Health Care REIT during the 3rd quarter worth approximately $200,000. Atria Investments LLC acquired a new stake in Sabra Health Care REIT during the 4th quarter worth approximately $208,000. Finally, FNY Partners Fund LP raised its holdings in Sabra Health Care REIT by 64.8% during the 4th quarter. FNY Partners Fund LP now owns 11,700 shares of the real estate investment trust’s stock worth $219,000 after buying an additional 4,600 shares during the period. Institutional investors and hedge funds own 88.88% of the company’s stock.

WARNING: This article was published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3341346/sabra-health-care-reit-inc-sbra-expected-to-announce-quarterly-sales-of-161-90-million.html.

About Sabra Health Care REIT

Sabra Health Care REIT, Inc is a real estate investment trust. The Company, through its subsidiaries, owns and invests in real estate serving the healthcare industry. The Company’s segment includes investments in healthcare-related real estate properties. The Company’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector.

Get a free copy of the Zacks research report on Sabra Health Care REIT (SBRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sabra Health Care REIT (NASDAQ:SBRA)

Receive News & Ratings for Sabra Health Care REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sabra Health Care REIT and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Swapcoin  1-Day Volume Hits $0.00
Swapcoin 1-Day Volume Hits $0.00
Bibox Token   Trading 9% Lower  Over Last Week
Bibox Token Trading 9% Lower Over Last Week
Farmers & Merchants Bancorp  & Umpqua  Financial Comparison
Farmers & Merchants Bancorp & Umpqua Financial Comparison
Analysts Set Southern  Price Target at $48.27
Analysts Set Southern Price Target at $48.27
Reviewing Dril-Quip  and Its Rivals
Reviewing Dril-Quip and Its Rivals
Pacific Premier Bancorp  Receives Average Recommendation of “Buy” from Analysts
Pacific Premier Bancorp Receives Average Recommendation of “Buy” from Analysts


Leave a Reply

© 2006-2018 Ticker Report. Google+.